Endometriosis Clinical Trials

Find Endometriosis Clinical Trials Near You

Risk Factors for Hormonal Therapy Failure in Patients With Endometriosis.

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

The primary objective of our study is to determine the percentage of patients with endometriosis who are non-responsive to medical therapy after 12 months and to compare the clinical and ultrasound characteristics of this group of patients (study group) with the clinical and ultrasound characteristics of patients who are responsive to medical therapy (control group). The secondary objective of the study will be to determine the percentage of patients with endometriosis who are non-responsive to medical therapy after 6 months and to compare the clinical and ultrasound characteristics of this group of patients (study group) with the clinical and ultrasound characteristics of patients who are responsive to medical therapy (control group).

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Maximum Age: 50
Healthy Volunteers: f
View:

• Age between 18 and 50 years;

• Patients with painful symptoms related to endometriosis (dyspareunia, dyschezia, dysmenorrhea, chronic pelvic pain, dysuria, periovulatory pain, with at least one of these symptoms presenting a Numerical Pain Rating Scale intensity \> 5);

• Indication for the administration of oral hormonal medical therapy for endometriosis;

• Acquisition of informed consent.

Locations
Other Locations
Italy
Policlinico Duilio-Casula
RECRUITING
Monserrato
Contact Information
Primary
Stefano Angioni, PhD
sangioni@yahoo.it
07051093399
Backup
Salvatore Giovanni Vitale, PHD
salvatoreg.vitale@unica.it
3479354575
Time Frame
Start Date: 2024-02-26
Estimated Completion Date: 2026-05-31
Participants
Target number of participants: 247
Treatments
Group A
Patients with endometriosis who are non-responsive to medical therapy after 12 months
Group B
Patients with endometriosis who are responsive to medical therapy after 12 months
Related Therapeutic Areas
Sponsors
Leads: University of Cagliari

This content was sourced from clinicaltrials.gov